PureTech Health plc (LON:PRTC – Get Free Report) shares traded up 14.2% during mid-day trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares traded hands during trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.43).
PureTech Health Stock Up 14.2%
The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The firm has a market cap of £293.65 million, a price-to-earnings ratio of 714.71 and a beta of 1.02. The firm has a 50 day moving average price of GBX 129.46 and a 200-day moving average price of GBX 129.72.
Insider Activity
In other news, insider Bharatt Chowrira purchased 167,739 shares of the business’s stock in a transaction dated Thursday, July 3rd. The shares were acquired at an average price of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is owned by company insiders.
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Further Reading
- Five stocks we like better than PureTech Health
- Industrial Products Stocks Investing
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- What is Forex and How Does it Work?
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.